477.7±45.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:477-32-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
Background: There is a growing interest on women’ sexual function improvement provided by topical vulvar application of Visnadine, a natural extractive substance with putative vasodilatory properties. Aims of this study were to evaluate: 1) the vasokinetic activity of a Visnadine Emulgel on mucosal genitalia of 15 healthy postmenopausal women clinically and by instrumental non-invasive analysis; 2) the treatment efficacy by volunteers’ judgment regarding to subjective comfort, pleasant warmth, lubrication grade, pinching and burning vulvar sensations.
Methods: Fifteen informed healthy female volunteers with menopause were enrolled in the study, with a single blind controlled study versus placebo corresponding to one single application of the emulgel product (active or placebo) on external genitalia.
Results: Visnadine Emulgel single application determined a significant increase of vulvar hyperemia, evaluated both clinically and instrumentally, accompanied by a significant increase of local turgor versus placebo. The volunteers reported a pleasant comfort sensation.
Conclusions: The topical use of Visnadine on female external genitalia may increase regional vascularization affecting turgidity and sensorial threshold of the area of application.
A randomized single-blind placebo-controlled study of a Visnadine Emulgel formulation on healthy postmenopausal women
Adele Sparavigna 1, Alberto Caputo 2, Alice Natoli 3, Clara Mandelli 4
Efficacy of an intimate oil solution containing visnadine in women self-reporting sexual symptoms
Alberto Caputo 1, Alice Natoli 1, Rossella Radice 2, Gabriele Zanardi 3, Luca Giacomelli 4
This single-arm pilot study enrolled 47 post-menopausal women affected by vulvovaginal atrophy (VVA). The Vaginal Health Index Score (VHIS) was evaluated for all women and all completed the Female Sexual Function Index (FSFI) questionnaire at baseline (T0) and after 15 days of vaginal cream treatment with one application per day (T1). Following treatment there was a significant improvement in all VHIS parameters and total score (p < 0.0001). Similarly, there was a significant improvement on four FSFI domains (lubrication, orgasm, satisfaction and pain) and total score (p = 0.001). None of the patients reported any local or systemic side-effects during treatment.
Bovine colostrum; Menopause; Prenylflavonoids; Sexual wellbeing; Visnadine; Vulvovaginal atrophy.
Preliminary results of a single-arm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually active women affected by vulvovaginal atrophy
Antonio Simone Laganà 1, Salvatore Giovanni Vitale 2, Lily Stojanovska 3, Irene Lambrinoudaki 4, Vasso Apostolopoulos 3, Benito Chiofalo 2, Laura Rizzo 2, Francesca Basile 2